Safety, Tolerability, and Pharmacokinetics Study of Human Monoclonal Antibody BRII-196
Status:
Completed
Trial end date:
2021-01-29
Target enrollment:
Participant gender:
Summary
This is a phase 1 study in which healthy adult volunteers will receive BRII-196 or placebo
and will be assessed for safety, tolerability, and pharmacokinetics.